CoChat

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14

Open access
Pratley, Richard E., Husain, Mansoor, Lingvay, Ildiko, Pieber, Thomas R., Mark, Thomas, Saevereid, Hans A., Møller, Daniel Vega, Zinman, Bernard, the DEVOTE Study Group · 2019 · Cardiovascular Diabetology

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Background: Heart failure (HF) is a common cardiovascular complication of type 2 diabetes (T2D). This secondary analysis investigated baseline factors and treatment differences associated with risk of hospitalization for HF (hHF), and the possible association between severe hypoglycemia and hHF. Methods: DEVOTE was a treat-to-target, double-blind cardiovascular outcomes trial in patients (n = 7637) with T2D and high cardiovascular risk randomized to insulin degludec (degludec) or insulin glargine 100 units/mL (glargine U100). The main endpoint of this secondary analysis was time to first hHF (standardized MedDRA Query definition). Severe hypoglycemia was adjudicated (American Diabetes Association definition). The main endpoint and the temporal association between severe hypoglycemia and hHF were analyzed with a Cox proportional hazards regression model. Predictors of time to first hHF were identified using baseline variables. Results: Overall, 372 (4.9%) patients experienced hHF (550 events). There was no significant difference in the risk of hHF between treatments (hazard ratio [HR] 0.88 [0.72;1.08]95% CI, p = 0.227). Prior HF (HR 4.89 [3.90;6.14]95% CI, p ≤ 0.0001) was the strongest predictor of future hHF events. The risk of hHF significantly increased after (HR 2.2), and within a week after (HR 11.1), experiencing a severe hypoglycemic episode compared with before an episode. Conclusions: In patients with T2D and high cardiovascular risk there were no treatment differences in terms of hHF. Prior HF was the strongest predictor of future hHF events, and there was an association between severe hypoglycemia and subsequent hHF. Further research should evaluate whether the risk of hHF can be modified by treatments aimed at reducing hypoglycemia. Trial Registration NCT01959529

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-019-0960-8

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Main and sensitivity analyses of treatment differences in time to first hHF (SMQ definition). *Broad MedDRA search weighted by proportion confirmed in LEADER by the Event Adjudication Committee. There were only 100 events using the broad MedDRA search without the LEADER match, 31 of which were classed as cardiac disorders. CI confidence interval, glargine U100 insulin glargine 100 units/mL, hHF hospitalization for heart failure, HF heart failure, N number of patients, % proportion of patients, SMQ standardized Medical Dictionary for Regulatory Activities Query
Fig. 1 Main and sensitivity analyses of treatment differences in time to first hHF (SMQ definition). *Broad MedDRA search weighted by proportion confirmed in LEADER by the Event Adjudication Committee. There were only 100 events using the broad MedDRA search without the LEADER match, 31 of which were classed as cardiac disorders. CI confidence interval, glargine U100 insulin glargine 100 units/mL, hHF hospitalization for heart failure, HF heart failure, N number of patients, % proportion of patients, SMQ standardized Medical Dictionary for Regulatory Activities QueryCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 1

  1. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels: International Diabetes Federation; 2015.

Cited by

See all 25

Metadata

Authors
Pratley, R. E., Husain, M., Lingvay, I., Pieber, T. R., Mark, T., Saevereid, H. A., Møller, D. V., Zinman, B., & the DEVOTE Study Group
Affiliations
  • Translational Research Institute for Metabolism and Diabetes (US)
  • University Health Network (CA)
  • The University of Texas Southwestern Medical Center (US)
  • Medical University of Graz (AT)
  • Novo Nordisk (Denmark) (DK)
  • Mount Sinai Hospital (CA)
Corresponding author
Pratley, Richard E.
Venue
Cardiovascular Diabetology
Published
2019-11-15
Volume
18
Issue
1
Pages
156-156
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2989460275
Cited by
25
References
51
Citations by year
2026: 4 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 2
FWCI
2.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • TSpace (University of Toronto) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
heart failure hospitalization, type 2 diabetes, insulin degludec, insulin glargine U100, severe hypoglycemia, high cardiovascular risk, basal insulin therapy
MeSH terms
Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Failure, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Patient Admission, Prospective Studies, Risk Factors, Time Factors, Biomarkers, Treatment Outcome, Disease Progression, Risk Assessment, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. https://app.cochat.ai/papers/10.1186/s12933-019-0960-8
The paper
Pratley, R. E., Husain, M., Lingvay, I., Pieber, T. R., Mark, T., Saevereid, H. A., Møller, D. V., Zinman, B., & the DEVOTE Study Group. (2019). Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-019-0960-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.